HK inno.N Corporation
195940.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.12T
Close$
$15016.34
58.3% downside
Current Fair Value
58.3% downsideOvervalued by 58.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.12 Trillion |
|---|---|
| Enterprise Value | $1.51 Trillion |
| Dividend Yield | $410.00 (1.03%) |
| Earnings per Share | $2672.09 |
| Beta | 0.53 |
| Outstanding Shares | 28,330,000 |
Return
| Return on Equity | 6.36% |
|---|---|
| Return on Assets | 4.24% |
| Return on Invested Capital | 8.40% |
Valuation & Multiples
| P/E Ratio | 13.1 |
|---|---|
| PEG | 96.67 |
| Price to Sales | 0.95 |
| Price to Book Ratio | 0.76 |
| Enterprise Value to Revenue | 1.4 |
| Enterprise Value to EBIT | 11.74 |
| Enterprise Value to Net Income | 17 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 0.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$721.00
Average shareholder expectationRevenue Estimate
$267.80 B
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$594.00
Average shareholder expectationRevenue Estimate
$270.98 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About HK inno.N Corporation
1,723 employees
CEO: Dal-Won Kwak Founded in 1984 and headquartered in Cheongju-si, South Korea, HK inno.N Corporation operates as a pharmaceutical enterprise. The company boasts a comprehensive portfolio of prescription medications designed to address a wide array of me...